262 related articles for article (PubMed ID: 15944795)
1. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
3. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
4. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
5. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Philips M; Juul AG; Selmer J; Lind B; Thorsen S
Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activators and cancer.
Duffy MJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):681-7. PubMed ID: 2133247
[TBL] [Abstract][Full Text] [Related]
7. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
8. Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Niwano H; Takahashi H; Tatewaki W; Wada K; Seki Y; Shibata A
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):389-93. PubMed ID: 1420814
[TBL] [Abstract][Full Text] [Related]
9. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.
Hildenbrand R; Dilger I; Hörlin A; Stutte HJ
Pathol Res Pract; 1995 Jun; 191(5):403-9. PubMed ID: 7479358
[TBL] [Abstract][Full Text] [Related]
12. [Study on the plasma plasminogen activators in patients with malignant gynecologic tumors].
Shimada H; Ikeuchi M; Suwa M; Michimoto T; Ono Y; Tanada S; Himeno K; Hoshino T; Takashima E
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1353-9. PubMed ID: 2511260
[TBL] [Abstract][Full Text] [Related]
13. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer.
Grøndahl-Hansen J; Agerlin N; Munkholm-Larsen P; Bach F; Nielsen LS; Dombernowsky P; Danø K
J Lab Clin Med; 1988 Jan; 111(1):42-51. PubMed ID: 3121772
[TBL] [Abstract][Full Text] [Related]
14. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay.
Rånby M; Nguyen G; Scarabin PY; Samama M
Thromb Haemost; 1989 Jun; 61(3):409-14. PubMed ID: 2508254
[TBL] [Abstract][Full Text] [Related]
15. Plasmin-catalyzed proteolysis in colorectal neoplasia.
Delbaldo C; Cunningham M; Vassalli JD; Sappino AP
Cancer Res; 1995 Oct; 55(20):4688-95. PubMed ID: 7553650
[TBL] [Abstract][Full Text] [Related]
16. Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone.
Leloup G; Peeters-Joris C; Delaisse JM; Opdenakker G; Vaes G
J Bone Miner Res; 1991 Oct; 6(10):1081-90. PubMed ID: 1796756
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Reilly D; Andreasen PA; Duffy MJ
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
[TBL] [Abstract][Full Text] [Related]
18. [Plasminogen activators and plasminogen activator inhibitor type-1 in human endometrium].
Chen GA; Feng Q; Zhang LZ; Liu YX
Sheng Li Xue Bao; 1992 Oct; 44(5):502-9. PubMed ID: 1293766
[TBL] [Abstract][Full Text] [Related]
19. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
[TBL] [Abstract][Full Text] [Related]
20. Detection of the plasmin system in human mammary pathology using immunofluorescence.
Clavel C; Chavanel G; Birembaut P
Cancer Res; 1986 Nov; 46(11):5743-7. PubMed ID: 2428483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
